CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
← catalyst calendarNCT05143996 · readout ≤ 165 d
Sponsored by Cullinan Therapeutics Inc. (industry) · CGEM — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
60estimated
Sites
11
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-11-18 | actual | When the study began enrolling |
| Primary completion | Jan 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jun 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2021-12-03 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-01-16 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Relapsed/Refractory Acute Myeloid Leukemia (AML)
- Myelodysplastic Syndrome (MDS)
Intervention
- Drug: CLN-049
Primary outcomes
what the primary-completion date above is the date OFNumber of treatment emergent events (TEAEs)
measured 28 days
Cmax of CLN-049
measured 28 Days
Ctrough of CLN-049
measured 28 Days
Tmax of CLN-049
measured 28 Days
T1/2 of CLN-049
measured Up to 28 days
Permalink · CGEM's whole pipeline · Catalyst calendar · Every registered study · What changed